Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE N/A. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $371697 | $518754 | $175M | $2.4B | $5.9B | $5.7B |
| Enterprise Value | $164834 | $311891 | $175M | $2.4B | $5.9B | $5.7B |
| P/E Ratio → | -0.06 | — | — | — | — | — |
| P/S Ratio | 0.19 | 0.27 | 3477.45 | — | — | — |
| P/B Ratio | — | — | — | 95.93 | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.16 | 3487.02 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | 57.2% | 57.2% | 87.4% | — | — | — |
| Operating Margin | -371.6% | -371.6% | -9933.8% | — | — | — |
| Net Profit Margin | -361.0% | -361.0% | -20605.5% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | — | — | -103.5% | -62.4% | — | — |
| ROA | -359.6% | -359.6% | -31.7% | -47.0% | -547.6% | -416.1% |
| ROIC | — | — | -38.0% | — | — | — |
| ROCE | — | — | -47.5% | -52.4% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.09 | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | -0.03 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -376.13 | -376.13 | -218.27 | -17.22 | -1.41 | -0.13 |
Net cash position: cash ($706740) exceeds total debt ($499877)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.25 | 0.25 | 0.16 | 1.63 | 0.08 | 0.01 |
| Quick Ratio | 0.12 | 0.12 | 0.14 | 1.63 | 0.08 | 0.01 |
| Cash Ratio | 0.09 | 0.09 | 0.03 | 0.08 | 0.02 | 0.05 |
| Asset Turnover | — | 0.81 | 0.03 | — | — | — |
| Inventory Turnover | 0.85 | 0.85 | 0.06 | — | — | — |
| Days Sales Outstanding | — | 6.96 | 2219.20 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $21M | $21M | $20M | $20M |
Imminent liquidity and insolvency
According to current market data, XAGE trades at a P/S ratio of 0.23, which appears to reflect extreme investor skepticism regarding the company's ability to achieve commercial scale rather than a genuine valuation of its underlying intellectual property or future clinical trial success in the regenerative medicine space.
The low P/S multiple suggests that the market is pricing the company as a distressed asset rather than a growth-stage biotech. Investors should monitor whether this valuation gap represents a deep-value opportunity or a rational assessment of the company's inability to convert its PBM platform into sustainable, high-margin revenue streams.
Based on reported financial figures, XAGE's ROIC has trended into negative territory, dropping from a positive 6.3% in 2023Q4 to -8.9% by 2024Q1, which indicates that the company is currently destroying shareholder value rather than compounding it through its ongoing research and development activities.
The rapid decay in returns on capital suggests that the company's heavy investment in clinical trials and infrastructure is not yielding proportional economic benefits. This trend warrants further investigation into whether the current management team can pivot toward a more capital-efficient model before the existing resource base is fully exhausted.
As reported in recent financial statements, XAGE's cash conversion cycle remains highly erratic, with figures swinging to extreme negative levels, suggesting that the company's reliance on lumpy, non-recurring orders creates significant friction in managing day-to-day liquidity and supplier relationships compared to more stable industry peers.
The extreme volatility in DSO and DPO metrics indicates that the company lacks a predictable revenue cadence, which complicates cash flow forecasting. Investors should be wary of these fluctuations, as they may mask underlying issues in customer payment terms or an inability to negotiate favorable credit terms with critical suppliers.
Based on the 2026Q1 financial statements, XAGE's current ratio has deteriorated to a precarious 0.15, signaling that the company's liquid assets are insufficient to cover its short-term liabilities, thereby placing the firm in a vulnerable position that likely necessitates immediate and potentially dilutive external capital intervention.
The company's inability to maintain a current ratio above 1.0 suggests that it is operating on the brink of a liquidity crisis. This situation implies that any delay in clinical milestones or a shortfall in projected sales could lead to an inability to meet operational obligations, heightening the risk of insolvency.
Analysts frequently misapply the revenue growth metric to XAGE, as the reported 3701% YoY surge obscures the reality that such growth is likely driven by one-time stocking orders rather than recurring end-user demand, which is a common pitfall when evaluating early-stage biotech firms with limited commercial history.
Focusing on top-line growth in this context ignores the underlying cash burn and the lack of a sustainable business model. Investors should instead prioritize the 'Cash Runway' and 'Surgeon Trial Rate' metrics, which provide a more accurate picture of the company's viability than the volatile and potentially misleading revenue figures.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying XAGE stock.
Longevity Health Holdings Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Based on historical data, Longevity Health Holdings Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Longevity Health Holdings Inc. has 57.2% gross margin and -371.6% operating margin.